$1,520,000 of HUMANA INC lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Medicare Advantage (MA) Policy and Reimbursement Medicare Part D Issues Medicaid Policy Issues Including Dual Eligibles Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues Home Health Policy and Reimbursement Issues Implementation of Inflation Reduction Act of 2022 Public Law No. 117-169 H.R. 3514/S.1816, Improving Seniors' Timely Access to Care Act of 2025 (119th Congress) Prior Authorization Policy and Regulatory Issues CMS-4185-F2 Medicare Advantage Risk Adjustment Data Validation Final Rule Primary Care and Value-Based Care Policy and Reimbursement Clinical Policy Issues Including Workforce and Mental Health Hospital Outpatient Prospective Payment System (OPPS): Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 Final Rule (CMS 1793-F) Implementation of CMS Interoperability and Prior Authorization final rule (CMS-0057-F) Contract Year 2025 Medicare Advantage and Part D Final Rule (CMS-4205-F) Announcement of Calendar Year (CY) 2025 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies Final Calendar Year (CY) 2025 Part D Redesign Program Instructions PL 119-21, One Big Beautiful Bill Act S.1105, No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act H.R. 3467, Medicare Advantage Reform Act Policy issues related to VA-eligible Medicare beneficiaries Final Calendar Year (CY) 2026 Part D Redesign Program Instructions Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-F) Final Guidance for Medicare Drug Price Negotiation Program guidance for initial price applicability year 2028 CMS Health Tech Ecosystem initiative H.R. 1732, GUARD VA Benefits Act H.R. 5454/S. 2789, Medicare Advantage Prompt Pay Act Contract Year 2027 Medicare Advantage and Part D Final Rule (CMS-4208-F3/CMS-4212-F) Calendar Year (CY) 2027 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (the CY 2027 Rate Announcement) 2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P) Medicare Drug Price Negotiation Program Proposed Rule (CMS-4215-P) Healthcare cybersecurity and Artificial Intelligence (AI) policy issues Request for Information (RFI): Pharmacy Benefit Manager Compensation and Data Collection (CMS-4218-NC) Consolidated Appropriations Act of 2026 Fiscal Year 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements Final Rule (CMS-1851-F) Fiscal Year 2027 Skilled Nursing Facility Prospective Payment System Final Rule (CMS 1843-F) Manufacturer Effectuation of MFP Draft Guidance for 2028 Medicare Drug Price Negotiation Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Calendar Year (CY) 2027 Home Health Prospective Payment System Proposed Rule (CMS-1844-P) Request for Information (RFI): Medicare Part D Reasonable and Relevant Pharmacy Contracting Standards (CMS-4217-NC) TRICARE Policy Issues including Telehealth, Value-Based Care, and T-5 Transition NDAA Implementation Policy Issues Veterans' Healthcare and Policy Issues H.R. 8800/S.4784: National Defense Authorization Act for Fiscal Year 2027 Tax Reform Implementation Issues PL 119-21, One Big Beautiful Bill Act Prescription drug pricing Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
HUM Hedge Fund Activity
We have seen 511 institutional investors add shares of HUM stock to their portfolio, and 368 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 3,234,637 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,284,862,509
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,370,831 shares (+inf%) to their portfolio in Q2 2026, for an estimated $544,521,489
- ASSENAGON ASSET MANAGEMENT S.A. added 1,249,272 shares (+20126.8%) to their portfolio in Q3 2026, for an estimated $476,684,717
- PZENA INVESTMENT MANAGEMENT LLC removed 1,067,846 shares (-19.5%) from their portfolio in Q2 2026, for an estimated $424,169,788
- CAPITAL WORLD INVESTORS added 927,924 shares (+981.9%) to their portfolio in Q2 2026, for an estimated $368,589,971
- INVESCO LTD. removed 907,025 shares (-38.0%) from their portfolio in Q2 2026, for an estimated $360,288,470
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 904,125 shares (-20.2%) from their portfolio in Q2 2026, for an estimated $359,136,532
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HUM Analyst Ratings
Wall Street analysts have issued reports on $HUM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 04/30/2026
To track analyst ratings and price targets for HUM, check out Quiver Quantitative's $HUM forecast page.
HUM Price Targets
Multiple analysts have issued price targets for $HUM recently. We have seen 14 analysts offer price targets for $HUM in the last 6 months, with a median target of $320.0.
Here are some recent targets:
- Ben Hendrix from RBC Capital set a target price of $415.0 on 07/09/2026
- Sarah James from Cantor Fitzgerald set a target price of $300.0 on 07/07/2026
- Kevin Fischbeck from B of A Securities set a target price of $380.0 on 06/24/2026
- Elizabeth Suzuki from Evercore ISI Group set a target price of $370.0 on 06/11/2026
- Lisa Gill from JP Morgan set a target price of $316.0 on 06/08/2026
- Ann Hynes from Mizuho set a target price of $390.0 on 06/08/2026
- Erin Wright from Morgan Stanley set a target price of $249.0 on 06/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
